Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

Autor: Ana Fernández, Mercedes Salgado, Adelaida García, Elvira Buxò, Ruth Vera, Jorge Adeva, Paula Jiménez-Fonseca, Guillermo Quintero, Cristina Llorca, Mamen Cañabate, Luis Jesús López, Andrés Muñoz, Patricia Ramírez, Paula González, Carlos López, Margarita Reboredo, Elena Gallardo, Manuel Sanchez-Cánovas, Javier Gallego, Carmen Guillén, Nuria Ruiz-Miravet, Víctor Navarro-Pérez, Juan De la Cámara, Inmaculada Alés-Díaz, Roberto Antonio Pazo-Cid, Alberto Carmona-Bayonas

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)

Abstract Background Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide

Externí odkaz: https://doaj.org/article/9fb8c852c86a46288b6abc44c57cd6fc

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

Autor: Elena Élez, María Auxiliadora Gómez-España, Cristina Grávalos, Pilar García-Alfonso, María José Ortiz-Morales, Ferrán Losa, Inmaculada Alés Díaz, Begoña Graña, Marta Toledano-Fonseca, Manuel Valladares-Ayerbes, Eduardo Polo, Mercedes Salgado, Eva Martínez de Castro, María José Safont, Antonieta Salud, Ana Ruiz-Casado, Josep Tabernero, María del Carmen Riesco, Antonio Rodriguez-Ariza, Enrique Aranda

Publikováno v: Br J Cancer

[Background] Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f48a8580d2d85d770659b388b474173
https://hdl.handle.net/10668/19521

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

Autor: Paula Jiménez-Fonseca, R. Vera, Patricia Ramírez, Manuel Sánchez-Cánovas, Elena Gallardo, Juan De la camara, Javier Gallego, Margarita Reboredo, Inmaculada Alés-Díaz, Paula González, Nuria Ruiz-Miravet, Carlos F. Lopez, Cristina Llorca, Carmen Guillén, Andrés Muñoz, Roberto Pazo-Cid, Ana María Fernández, Mamen Cañabate, Jorge Adeva, Adelaida García, Elvira Buxó, Víctor Navarro-Pérez, Guillermo Quintero, Luis Jesús López, Alberto Carmona-Bayonas, Mercedes Salgado

Publikováno v: Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
BMC Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica

Background: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e26323259b3ceea687237138c50f0db8
http://zaguan.unizar.es/record/76952

Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency

Autor: Ana Maria Galeote-Miguel, Maria José Bermejo-Pérez, Manuel Benavides-Orgaz, Inmaculada Alés-Díaz, Luis Enrique Rodelo-Haad, Gema Durán-Ogalla

Publikováno v: Chemotherapy. 60:353-355

Dihydropyrimidine dehydrogenase (DPD) is a metabolic enzyme that is crucial in 5-fluorouracil (5-FU) degradation. A deficiency in it is associated with the occurrence of adverse events following fluoropyrimidine-based therapies. We describe a case of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45071d4c0a9978d6693013f4f705cc3
https://doi.org/10.1159/000438665

Bronchiolitis obliterans organizing pneumonia simulating progression in bronquioloalveolar carcinoma

Autor: Julia Alcaide García, Manuel Benavides Orgaz, Ester Villar Chamorro, Silvia Gil Calle, Vanesa Gutiérrez Calderón, Manuel Cobo Dols, Inmaculada Alés Díaz

Publikováno v: Clinical and Translational Oncology. 8:133-135

Bronchiolitis obliterans organizing pneumonia (BOOP) is a clinicopathologic syndrome with characteristic features. The diagnosis of BOOP requires the presence of a combination of pathological, clinical, and radiological features. We report the case o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8329343628d4ea1b91393fff3e0bcd5f
https://doi.org/10.1007/s12094-006-0171-0